Tirzepatide Once Weekly for the Treatment of Obesity
Open accessThe DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Obesity is a chronic disease that results in substantial global morbidity and mortality. The efficacy and safety of tirzepatide, a novel glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist, in people with obesity are not known. METHODS: In this phase 3 double-blind, randomized, controlled trial, we assigned 2539 adults with a body-mass index (BMI; the weight in kilograms divided by the square of the height in meters) of 30 or more, or 27 or more and at least one weight-related complication, excluding diabetes, in a 1:1:1:1 ratio to receive once-weekly, subcutaneous tirzepatide (5 mg, 10 mg, or 15 mg) or placebo for 72 weeks, including a 20-week dose-escalation period. Coprimary end points were the percentage change in weight from baseline and a weight reduction of 5% or more. The treatment-regimen estimand assessed effects regardless of treatment discontinuation in the intention-to-treat population. RESULTS: At baseline, the mean body weight was 104.8 kg, the mean BMI was 38.0, and 94.5% of participants had a BMI of 30 or higher. The mean percentage change in weight at week 72 was -15.0% (95% confidence interval [CI], -15.9 to -14.2) with 5-mg weekly doses of tirzepatide, -19.5% (95% CI, -20.4 to -18.5) with 10-mg doses, and -20.9% (95% CI, -21.8 to -19.9) with 15-mg doses and -3.1% (95% CI, -4.3 to -1.9) with placebo (P<0.001 for all comparisons with placebo). The percentage of participants who had weight reduction of 5% or more was 85% (95% CI, 82 to 89), 89% (95% CI, 86 to 92), and 91% (95% CI, 88 to 94) with 5 mg, 10 mg, and 15 mg of tirzepatide, respectively, and 35% (95% CI, 30 to 39) with placebo; 50% (95% CI, 46 to 54) and 57% (95% CI, 53 to 61) of participants in the 10-mg and 15-mg groups had a reduction in body weight of 20% or more, as compared with 3% (95% CI, 1 to 5) in the placebo group (P<0.001 for all comparisons with placebo). Improvements in all prespecified cardiometabolic measures were observed with tirzepatide. The most common adverse events with tirzepatide were gastrointestinal, and most were mild to moderate in severity, occurring primarily during dose escalation. Adverse events caused treatment discontinuation in 4.3%, 7.1%, 6.2%, and 2.6% of participants receiving 5-mg, 10-mg, and 15-mg tirzepatide doses and placebo, respectively. CONCLUSIONS: In this 72-week trial in participants with obesity, 5 mg, 10 mg, or 15 mg of tirzepatide once weekly provided substantial and sustained reductions in body weight. (Supported by Eli Lilly; SURMOUNT-1 ClinicalTrials.gov number, NCT04184622.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Many patients treated with GLP-1RAs achieve clinically meaningful weight loss while simultaneously demonstrating improvements in cardiometabolic health.45,46”
From Receipt of Glucagon-Like Peptide-1 Receptor Agonists Among Rural Patients with Obstructive Sleep Apnea and Excess Weight (2026) · cites this paper as [46]
In the citing paper
“with two articles presenting LM outcomes in only a subset of participants from the parent trial (6, 7).”
From G LP1Ra ‐based therapies and DXA ‐acquired musculoskeletal health outcomes: a focused meta‐analysis of placebo‐controlled trials (2025) · cites this paper as [7]
In the citing paper
“Indeed, clinical trials demonstrate substantial weight loss achievable with GLP1Ra-based therapy, ranging from 12-15% over a one-year period for semaglutide (6), to weight losses rivaling what is seen with bariatric surgery for tirzepatide (7).”
From G LP1Ra ‐based therapies and DXA ‐acquired musculoskeletal health outcomes: a focused meta‐analysis of placebo‐controlled trials (2025) · cites this paper as [7]
In the citing paper
“Across body weight and composition outcomes, the greatest magnitude of weight loss was observed in the SURMOUNT (7) and STEP (6) trials, respectively.”
From G LP1Ra ‐based therapies and DXA ‐acquired musculoskeletal health outcomes: a focused meta‐analysis of placebo‐controlled trials (2025) · cites this paper as [7]
In the citing paper
“However, the magnitude of the treatment effect on total body mass was nearly two times greater in trials using GLP1Ra-based therapies at dosages indicated primarily for chronic weight management (6, 7, 18, 21, 24) as compared to trials using dosages indicated primarily for diabetes management (17, 19, 20, 22): −10.2 kg (−16.3, −3.9) versus −5.5 kg (−8.7, −2.1), respectively.”
From G LP1Ra ‐based therapies and DXA ‐acquired musculoskeletal health outcomes: a focused meta‐analysis of placebo‐controlled trials (2025) · cites this paper as [7]
174 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205
Self-citationObesity and cardiovascular disease: a scientific statement from the American Heart Association
Powell-Wiley, T. M., Poirier, P., Burke, L. E., Després, J.-P., Gordon-Larsen, P., Lavie, C. J., Lear, S. A., Ndumele, C. E., Neeland, I. J., Sanders, P., et al. (2021) · Circulation · doi:10.1161/cir.0000000000000973 · Cited by 3,691
Di Angelantonio, E., Bhupathiraju, S. N., Wormser, D., Gao, P., Kaptoge, S., de Gonzalez, A. B., Cairns, B. J., Huxley, R., Jackson, C. L., Joshy, G., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30175-1 · Cited by 2,821
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411892 · Cited by 2,724
2. Classification and Diagnosis of Diabetes:Standards of Medical Care in Diabetes—2019
American Diabetes Association (2019) · Diabetes Care · doi:10.2337/dc19-s002 · Cited by 2,697
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
Frías, J. P., Davies, M. J., Rosenstock, J., Pérez Manghi, F. C., Fernández Landó, L., Bergman, B. K., Liu, B., Cui, X., & Brown, K. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107519 · Cited by 2,096
Self-citationGarvey, W. T., Mechanick, J. I., Brett, E. M., Garber, A. J., Hurley, D. L., Jastreboff, A. M., Nadolsky, K., Pessah-Pollack, R., & Plodkowski, R. (2016) · Endocrine Practice · doi:10.4158/ep161365.gl · Cited by 1,914
Self-citationObesity in adults: a clinical practice guideline
Wharton, S., Lau, D. C. W., Vallis, M., Sharma, A. M., Biertho, L., Campbell-Scherer, D., Adamo, K., Alberga, A., Bell, R., Boulé, N., et al. (2020) · Canadian Medical Association Journal · doi:10.1503/cmaj.191707 · Cited by 1,506
Self-citationRubino, D., Abrahamsson, N., Davies, M., Hesse, D., Greenway, F. L., Jensen, C., Lingvay, I., Mosenzon, O., Rosenstock, J., Rubio, M. A., et al. (2021) · JAMA · doi:10.1001/jama.2021.3224 · Cited by 1,444
Davies, M., Færch, L., Jeppesen, O. K., Pakseresht, A., Pedersen, S. D., Perreault, L., Rosenstock, J., Shimomura, I., Viljoen, A., Wadden, T. A., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00213-0 · Cited by 1,419
Cited by
Items 1,201–1,300 of 3,704
Statin Use and Hyperglycemia: Do Statins Cause Diabetes?
Bredefeld, C., Choi, P., Cullen, T., Nicolich-Henkin, S., & Waters, L. (2024) · Current Atherosclerosis Reports · doi:10.1007/s11883-024-01266-8 · Cited by 11
“GLP-1RAs originally approved for the treatment of type 2 diabetes are now FDA approved for weight management [78, 82].”
Ard, J. D., Ryan, D. H., O'Neil, P. M., Kushner, R. F., Wyatt, H. R., Bays, H. E., Greenway, F. L., Jakicic, J. M., Leonard, S. M., Kenan, Y., et al. (2025) · Obesity · doi:10.1002/oby.24240 · Cited by 9
Cazac, G.-D., Lăcătușu, C.-M., Grigorescu, E.-D., Foșălău, A.-B., Onofriescu, A., & Mihai, B. M. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14041042 · Cited by 10
“Tirzepatide, a dual GIP and GLP-1 receptor agonist, also known as a “twincretin,” was approved by the Food and Drug Administration (FDA) in May 2022 to treat T2DM and in 2023 for chronic weight management [61,62].”
Carmichael, C., Jouravskaya, I., Collins, E., Burns, D. S., Poon, J. L., Kitchen, H., Mojdami, D., Murphy, M., Ahmad, N. Y., & Kanu, C. (2025) · Patient · doi:10.1007/s40271-025-00730-0 · Cited by 15
Self-citationMetabolic Improvements With Tirzepatide in Lipodystrophy: A Novel Option?
Meral, R., Güler, M. Ç., Kaba, D., Prativadi, J., Frontera, E. D., Foss‐Freitas, M. C., Nachawi, N., Broome, D. T., Lightbourne, M., Brown, R. J., et al. (2025) · Diabetes Care · doi:10.2337/dc24-2408 · Cited by 19
Sevencan, B., Steenackers, N., van Laar, A. D. E., Pazmiño, S., Buyse, B., Kalkanis, A., Testelmans, D., & der Schueren, B. V. (2025) · Journal of Clinical Sleep Medicine · doi:10.5664/jcsm.11682 · Cited by 10
The evolution of the therapeutic concept ‘GIP receptor antagonism’
Koefoed-Hansen, F., Helsted, M. M., Kizilkaya, H. S., Lund, A., ROSENKILDE, M. M., & Gasbjerg, L. S. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1570603 · Cited by 9
Przybyłowski, A., Górski, M. K., Gwioździk, W., & Polaniak, R. (2025) · Healthcare · doi:10.3390/healthcare13161967 · Cited by 18
“%) in recent trials, though full obesity approvals and long-term data remain limited within the last ten years [68].”
Sattar, N. A., Frühbeck, G., Andréelli, F., García‐Pérez, L., Cao, D., Stefański, A., Tangı, F., Grant, G., & Benabbad, I. (2025) · Diabetes Care · doi:10.2337/dc25-1442 · Cited by 13
Self-citationChronic Coronary Artery Disease
Kittleson, M. M. (2025) · Annals of Internal Medicine · doi:10.7326/annals-25-03512 · Cited by 12
Obesity phenotypes and atherogenic dyslipidemias
Choe, H. J., Almas, T., Neeland, I. J., Lim, S. K., & Després, J. (2025) · European Journal of Clinical Investigation · doi:10.1111/eci.70151 · Cited by 18
“195 It also reduced inflammatory markers such as high sensitivity C-reactive protein and improved cardiovascular risk biomarkers in post hoc analyses of SURPASS-4.”
New pharmacologic agents for obstructive sleep apnoea: what do we know and what can we expect?
Hedner, J. A., & Zou, D. (2022) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000000920 · Cited by 10
“1%) atweek 72 in overweight/obese nondiabetic patients [66].”
BackgroundWong, E., Cope, R. J., Dima, L., & Nguyen, T. K. (2022) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000001588 · Cited by 17
Koufakis, T., Liberopoulos, E. N., Kokkinos, A. D., Zebekakis, P. E., & Kotsa, K. (2023) · Drugs · doi:10.1007/s40265-023-01852-1 · Cited by 9
“5% for the efficacy estimand), and induced diabetes remission in almost 50% of patients treated with this agent in various trials, probably secondary to significant weight reductions [51].”
BackgroundDavies, I., & Tan, T. (2023) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2023.2203911 · Cited by 10
“4 mg semaglutide over a similar time frame [52].”
BackgroundStefanidis, A., Lee, C. M. C., Greaves, E., Montgomery, M. K., Arnold, M., Newn, S., Budin, A. J., Lemus, M. B., Foldi, C. J., Burton, P. R., et al. (2023) · Molecular Metabolism · doi:10.1016/j.molmet.2023.101739 · Cited by 12
“The efficacy of medicinal treatments for overweight and obesity is improving with the recent introduction of pharmacotherapies [1] that reliably produce at least 20% average weight losse a result that is dependent on ongoing medication.”
BackgroundDifferential Responses of the GLP-1 and GLP-2 Receptors to N-Terminal Modification of a Dual Agonist
Gibadullin, R., Cary, B. P., & Gellman, S. H. (2023) · Journal of the American Chemical Society · doi:10.1021/jacs.3c01628 · Cited by 10
Induction of remission in diabetes by lowering blood glucose
Weir, G. C., & Bonner‐Weir, S. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1213954 · Cited by 15
“Such drugs as long-acting drug tirzepatide (45) cause weight loss and stimulation of insulin secretion.”
BackgroundBain, S. C., & Min, T. (2023) · The Lancet · doi:10.1016/s0140-6736(23)01182-0 · Cited by 9
The Emerging Role of Injectable Weight Loss Medications in Plastic Surgery: A Systematic Review
Shridharani, S. M., & Kohan, J. (2023) · Aesthetic Surgery Journal · doi:10.1093/asj/sjad240 · Cited by 12
Clinical and Therapeutic Implications of Male Obesity
Lenart-Lipińska, M., Łuniewski, M., Szydełko, J., & Matyjaszek‐Matuszek, B. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12165354 · Cited by 14
Metabolic and Bariatric Surgery in Children: Current Practices and Outcomes
Shah, S. A., Khan, N. A., & Qureshi, F. (2024) · Current Obesity Reports · doi:10.1007/s13679-023-00540-1 · Cited by 9
“A combination agent (GLP-1/GIP) tirzepatide has recently been shown to be much more effective in adults who struggle with obesity [23].”
Contemporary Treatments for Obesity: Physical Activity in the Context of Antiobesity Medications
Jakicic, J. M., Rogers, R. J., & Apovian, C. M. (2024) · Translational Journal of the American College of Sports Medicine · doi:10.1249/tjx.0000000000000253 · Cited by 10
Luo, Y., Ma, W., Cheng, S., Yuan, T., Li, J., Hao, H., Liu, K., Zeng, M., & Pan, Y. (2024) · Aesthetic Surgery Journal · doi:10.1093/asj/sjae070 · Cited by 11
A Revolution in the Treatment of Obesity
Spector, R. (2024) · The American Journal of Medicine · doi:10.1016/j.amjmed.2024.05.023 · Cited by 10
Talay, L., Vickers, M., & Ruiz, L. (2024) · Obesities · doi:10.3390/obesities4030021 · Cited by 10
“Glucose-like peptide-1 receptor agonists (GLP-1 RAs) have emerged in multiple efficacy trials as a promising form of obesity pharmacotherapy [2,3].”
BackgroundTirzepatide highly effective for weight loss
Tysoe, O. (2022) · Nature Reviews Endocrinology · doi:10.1038/s41574-022-00715-1 · Cited by 11
Khadanga, S., Barrett, K. V., Sheahan, K. H., & Savage, P. D. (2022) · Journal of Cardiopulmonary Rehabilitation and Prevention · doi:10.1097/hcr.0000000000000761 · Cited by 11
Cazac, G.-D., Lăcătușu, C.-M., Ștefănescu, G., Mihai, C., Grigorescu, E.-D., Onofriescu, A., & Mihai, B. M. (2023) · Metabolites · doi:10.3390/metabo13050581 · Cited by 10
Leuthardt, A. S., Boyle, C. N., Raun, K., Lutz, T. A., John, L. M., & Foll, C. L. (2023) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2023.175912 · Cited by 12
Cicuttini, F., Proietto, J., & Lim, Y. Z. (2023) · Osteoarthritis and Cartilage Open · doi:10.1016/j.ocarto.2023.100407 · Cited by 11
“A newer agent, tirzepatide [a GLP-1 and Gastric inhibitory polypeptide (GIP) dual agonist], has even higher rates of weight loss of 22.5% [39].”
BackgroundInfluentialPandey, R. K., Jan, M., Mohammad, A., Jawaid, K. A., Naveed, M., Abid, M. A., Amir, A. B., Ahmed, S., Safiullah, M., Bhatti, M. I., et al. (2025) · Endocrinology, Diabetes & Metabolism · doi:10.1002/edm2.70134 · Cited by 9
Jensen, S. B. K., Fiorenza, M., Juhl, C. R., Sandsdal, R. M., Jensen, E., Seier, S. S., Janus, C., Jørgensen, J. R., Blond, M. B., Holst, J. J., et al. (2026) · Sports Medicine · doi:10.1007/s40279-025-02386-0 · Cited by 9
“The phase III trials of liraglutide, semaglutide, and tirzepatide all showed improvements in self-reported physical functioning [14, 43, 44].”
Abdalla, M. A., Soyiri, I., Atkin, S., & Sathyapalan, T. (2023) · Journal of Diabetology · doi:10.4103/jod.jod_16_23 · Cited by 8
Health care providers' attitudes and counseling behaviors related to obesity
Smith, M., Gallagher, C., Weber, D., & Dietz, W. H. (2023) · Obesity Science & Practice · doi:10.1002/osp4.686 · Cited by 8
“For example, 35% of patients in a semaglutide trial and 63% of patients in a tirzepatide (15 mg dose) trial lost ≥20% of their body weight.(17,18) These findings emphasize the need for inclusion of obesity in medical school curricula, and training in the use of AOMs for interns, residents, and practicing PCPs.”
BackgroundVilarrasa, E., Nicolau, J., de la Cueva, P., Goday, A., Gallardo, F., Martorell, A., & Carrascosa, J. M. (2023) · Actas Dermo-Sifiliográficas · doi:10.1016/j.ad.2023.10.019 · Cited by 8
Minimizing Metabolic and Cardiac Risk Factors to Maximize Outcomes After Liver Transplantation
Schmidt, K., Spann, A., Khan, M. Q., Izzy, M. J., & Watt, K. D. S. (2023) · Transplantation · doi:10.1097/tp.0000000000004875 · Cited by 10
“35”
Approach to the Patient: Navigating Body Mass Index Requirements for Gender-Affirming Surgery
Taormina, J. M., Kissee, M. C., Brownstone, L. M., Grimstad, F. W., Morrison, S. D., Hendrixson, A., & Iwamoto, S. J. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae193 · Cited by 8
Remission of type 2 diabetes: position statement of the Italian society of diabetes (SID)
Capoccia, D., Leonetti, F., Natali, A., Tricò, D., Perrini, S., Sbraccia, P., Guglielmi, V., & On behalf of the Italian Society of Diabetes (SID) (2024) · Acta Diabetologica · doi:10.1007/s00592-024-02317-x · Cited by 11
Glucagon-Like Peptide 1 Receptor Agonists for Obesity: Efficacy, Side Effects, and Risks
Thota-Kammili, S., Tama, E., & Andrade, M. D. H. (2024) · Current Treatment Options in Gastroenterology · doi:10.1007/s11938-024-00452-6 · Cited by 10
The unexpected role of GIP in transforming obesity treatment
Zandvakili, I., & Pérez–Tilve, D. (2024) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2024.07.022 · Cited by 9
Interoception and Mental Health
Khalsa, S. S., & Verdonk, C. (2024) · Springer eBooks · doi:10.1007/978-3-031-68521-7_9 · Cited by 13
Zinn, J., & Poretsky, L. (2024) · AACE Clinical Case Reports · doi:10.1016/j.aace.2024.12.001 · Cited by 10
Nutrient-Stimulating Hormone-Based Therapies for Obesity
Cristancho, C., Kim, D. W., & Apovian, C. M. (2024) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2024.10.006 · Cited by 8
Behavioral medicine in the GLP-1 era
Tomiyama, A. J. (2024) · Annals of Behavioral Medicine · doi:10.1093/abm/kaae069 · Cited by 51
Oyama, R., Okuhara, T., Furukawa, E., Okada, H., & Kiuchi, T. (2025) · JMIR Formative Research · doi:10.2196/68792 · Cited by 11
“However, since participants in clinical trials evaluating the efficacy of obesity treatment drugs received medication therapy as an auxiliary to lifestyle interventions, the message that the use of GLP-1RAs for weight loss does not require exercise or dietary therapy is unscientific [48].”
DiStefano, M. J., Dardouri, M., Moore, G. D., Saseen, J. J., & Nair, K. V. (2024) · Journal of Pharmaceutical Policy and Practice · doi:10.1080/20523211.2024.2441220 · Cited by 13
“…and tirzepatide achieved between 14.9% and 20.9% reduction in body weight after one year, as well as improvement on cardio-vascular risk factors (Jastreboff et al., 2022; Wilding et al., 2021), leading to this class of drugs being hailed as ‘game changers’ for chronic weight management (Kolata,…”
InfluentialWhen Should the Treatment of Obesity in Thyroid Disease Begin?
Sutkowska, E., Kisiel, M., & Zubkiewicz‐Kucharska, A. (2025) · Biomedicines · doi:10.3390/biomedicines13010157 · Cited by 11
“The discovery of incretin hormones’ role not only in regulating blood glucose levels but also in regulating body weight has been a breakthrough in the treatment of T2DM [67–69], as well as in managing obesity without concurrent glucose metabolism disorders [70,71].”
Lam, B. P., Bartholomew, J., Bau, S., Gilles, H., Keller, A., Moore, A., Nader, K., Richards, L., Henry, L. L., & Younossi, Z. M. (2025) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0000000000002140 · Cited by 9
Zupec, J. F., Munger, R., Scaletta, A., & Quinn, D. H. (2025) · Nutrition in Clinical Practice · doi:10.1002/ncp.11279 · Cited by 9
Rasouli, N., Wilding, J. P. H., Kwan, A. Y. M., Paik, J. S., Sharma, P., & Peleshok, J. C. (2025) · Diabetes Therapy · doi:10.1007/s13300-025-01711-0 · Cited by 17
“Furthermore, in participants with obesity without diabetes, tirzepatide was not associated with an excess risk of hypoglycemia [7–9].”
Emerging Pharmacological Approaches for the Treatment of Arterial Hypertension
Schinzari, F., Montenero, R., Cardillo, C., & Tesauro, M. (2025) · Biomedicines · doi:10.3390/biomedicines13040790 · Cited by 10
New Frontiers in Nutritional and Therapeutic Interventions for Obesity Phenotypes
Patti, A. M., Giglio, R. V., Ciaccio, M., Stoian, A. P., Salmen, T., Bica, I.-C., Rangraze, I. R., El‐Tanani, M., Rizzo, M., & Rizvi, A. A. (2025) · Medicina · doi:10.3390/medicina61040664 · Cited by 9
“By 48 weeks after treatment initiation, participants had lost an average of 24 percent of their weight, more than any other drug on the market [28].”
Kurevija, T., Šojat, D., Bilić-Čurčić, I., Canecki-Varžić, S., & Majnarić, L. T. (2025) · BMC Family Practice · doi:10.1186/s12875-025-02837-7 · Cited by 9
“Conversely, GLP-1 RAs and the newer insulin secretion-stimulating medication tirzepatide are preferred for weight loss in obese individuals with T2D [13, 14].”
Successful Treatment of Hypothalamic Obesity with Tirzepatide
Brijmohan, S., & Mullally, J. A. (2025) · AACE Endocrinology and Diabetes · doi:10.1016/j.aed.2025.03.004 · Cited by 9
“13 Remarkably, our patient with HO achieved a signi fi cant weight loss of 9 kg ( (cid:4) 6.4”
InfluentialDavis, J. P. E., Reticker, A., Han, H. H., Orandi, B. J., Henry, Z. H., Tsunoda, S. M., Heimbach, J. K., Schulman, A. R., Tincopa, M. A., & the AST LICOP Controversies Conference Working Group (2025) · Liver Transplantation · doi:10.1097/lvt.0000000000000645 · Cited by 8
Molecular Design of Unimolecular Tetra-Receptor Agonists
Dinsmore, T. C., Cortigiano, J. E., Xiang, S., Spenciner, M. V., Dobbins, A. R., Zhao, R. R., Waldman, B. M., Beinborn, M., & Kumar, K. (2025) · Journal of the American Chemical Society · doi:10.1021/jacs.5c04095 · Cited by 13
Munawar, N., Mahato, A., Rawat, A., Gill, F. S., Kumar, D., Katwal, S., Wei, C. R., & Ali, N. (2025) · Cureus · doi:10.7759/cureus.86080 · Cited by 20
“Data from the SURpass-MOUnted Tirzepatide (SURMOUNT) clinical trials have shown reductions in body weight of up to 20.9%, establishing tirzepatide as a potent agent in obesity management [24,25].”
InfluentialSteenackers, N., Toumassian, J., Deleus, E., Mertens, A. C., Lannoo, M., Pazmiño, S., van Laar, A. D. E., der Schueren, B. V., & Vangoitsenhoven, R. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1569468 · Cited by 21
“This heterogeneity in Weight loss response per anti-obesity drug (19 – 21, 23, 25, 34, 35).”
Obesity: assessment and treatment across the care continuum
Kushner, R. F., & Marla Shapiro, C. M. (2025) · Annals of Medicine · doi:10.1080/07853890.2025.2521433 · Cited by 14
“For these patients, obesity medication such as weekly injectable semaglutide or tirzepatide that produce 17% to 23% reductions in body weight may be more appropriate [56,69].”
InfluentialGhusn, W., Divakar, A., Salameh, Y., Mosleh, K. A., & Storm, A. C. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14134681 · Cited by 9
“Traditional management approaches, including lifestyle modification and pharma-cotherapy (e.g., semaglutide and tirzepatide), have shown promising weight loss outcomes [4–6].”
Fu, W., Lin, J., You, C., Zhang, J., Lei, J., Zheng, L., Zheng, B., Liu, M., Liu, L., & Li, N. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16581 · Cited by 8
Pearson, E. R., Prato, S. D., Pavo, I. J., Franco, D. R., Zheng, J., Nicolay, C., Hemmingway, A., Wiese, R. J., & Kahn, S. E. (2025) · Diabetes · doi:10.2337/db25-0276 · Cited by 14
“…are supported by the larger weight loss of individuals without T2D receiving tirzepatide, and a similar observation was made with semaglutide (39,40). this analysis, the strongest predictor of reaching the weight loss target was female sex, with women twice as likely to reach weight loss ≥…”
Beyond Blood Sugar: A Scoping Review of GLP-1 Receptor Agonists in Cardiovascular Care
Gupta, N., Zayyad, Z. A., Bhattaram, R., Tiu, D. R., Dau, J., Guburxani, V., Kalzuna, S. D., & Shroff, A. R. (2025) · Cardiology and Therapy · doi:10.1007/s40119-025-00426-4 · Cited by 12
“In overweight or obese patients with no history of T2DM, tirzepatide achieved a significant approximately 6 mmHg SBP reduction in the SURMOUNT-1 trial [38].”
Dawwas, G. K., Samuels, J. M., & Stein, C. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16600 · Cited by 10
Wang, J., Chen, H., & Wang, X. (2025) · Journal of Biochemical and Molecular Toxicology · doi:10.1002/jbt.70392 · Cited by 9
Wang, D., Wang, J., Li, B., Yang, S., Guo, F., Zheng, B., & Wang, J. (2025) · Molecular Medicine · doi:10.1186/s10020-025-01312-4 · Cited by 10
“Clinical trials report nausea as a common side effect of GLP-1 agonists, which could be exacerbated by increased brain exposure (Jastreboff et al. 2022).”
CRISPR–Cas9 screening reveals microproteins regulating adipocyte proliferation and lipid metabolism
Pai, V. J., Shan, H., Donaldson, C. J., Vaughan, J. M., de Souza, E. V., O’Connor, C., Liem, M., Pinto, A. F. M., Diedrich, J. K., & Saghatelian, A. (2025) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2506534122 · Cited by 11
“Ribo - Seq uses ribosome footprinting on RNA to identify regions of active RNA translation ( 9 , 10 ).”
Xie, Z., Liang, Z., Xie, Y., Zheng, G., & Cao, W. (2025) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s537229 · Cited by 12
Herman, R., Jensterle, M., Horvat, S., Ležaić, L., Snoj, Ž., Pušnik, I., Goričar, K., Cör, A., Pušnik, L., Mlačnik, V., et al. (2025) · Trials · doi:10.1186/s13063-025-09045-9 · Cited by 14
“Limited yet consistent data from the STEP and SURMOUNT studies indicate beneficial changes in adipose tissue loss and distribution, with comparable or even lower lean mass loss compared to other weight loss interventions [36, 37].”
Hsu, C., Zeng, B., Liang, C., Zeng, B., Hung, C., Stubbs, B., Chen, Y., Lei, W., Chen, J.-J., Chen, P., et al. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26178202 · Cited by 12
Effect of incretin-based therapies on blood pressure: a systematic review and meta-analysis
Basile, C., Merolla, A., Mancusi, C., Luca, C. D., Fucile, I., Canonico, M. E., Giugliano, G., Orso, F., Morisco, C., & Esposito, G. (2025) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwaf560 · Cited by 17
The Impact of Glucagon-like Peptide-1 Receptor Agonists on Erectile Function: Friend or Foe?
Kounatidis, D. C., Vallianou, N. G., Rebelos, E., Vallianou, K., Diakoumopoulou, E., Makrilakis, K., & Tentolouris, N. (2025) · Biomolecules · doi:10.3390/biom15091284 · Cited by 15
“More recently, tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 receptor agonist, has demonstrated superior weight-reducing effects compared with both placebo and semaglutide, particularly in the SURMOUNT trials, with these benefits sustained for up to 72 weeks [79–81].”
Antiobesity Medications for Older Adults—the New, the Good, the Bad, and the Unknown
Pendrey, A., & Sevilla‐Martir, J. (2025) · Obesity · doi:10.1002/oby.70029 · Cited by 11
“The SURMOUNT-1 trial showed improved functional scores in the SF-36 in the tirzepatide group when compared to placebo at week 72 [50].”
Wawrzak-Pienkowska, K., Pienkowski, T., Golonko, A., Krupa, A., Warpechowski, M., Płoński, A. F., Mojsak, P., Daniluk, J., Dâbrowski, A., & Kurek, K. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.178290 · Cited by 12
le Roux, C. W., Wharton, S., Bozkurt, B., Platz, E., Bleckert, G., Hussain, S. A., Brueckmann, M., Startseva, E., Kloer, I. M., & Kaplan, L. M. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70196 · Cited by 9
“16 Because of the heterogeneous response to approved medications such as semaglutide and tirzepatide, 17,18 and evidence suggesting that some of their clinical benefits are related to therapeutic effects independent of weight loss, 19 there is interest in investigating compounds with complementary…”
Self-citationMinnetti, M., Barazzoni, R., Batsis, J. A., Busetto, L., Yumuk, V., Poggiogalle, E., Weijs, P. J. M., & Donini, L. M. (2025) · Obesity Facts · doi:10.1159/000548370 · Cited by 15
“They include a 500 kcal/day caloric deficit and recommend at least 150 min per week of moderate-intensity PA, with adherence self-monitored and reviewed during scheduled counseling sessions [1, 3, 70, 71, 92, 93].”
InfluentialLin, P., Zeng, B., Hsu, C., Suen, M., Hung, C., Stubbs, B., Chen, Y.-W., Chen, T., Lei, W., Chen, J.-J., et al. (2025) · Biomolecules · doi:10.3390/biom15111622 · Cited by 10
LEAP2 as a therapeutic target in obesity and cardiometabolic disorders
Holm, S. K., Johansen, V. B. I., & Clemmensen, C. (2025) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-025-10007-4 · Cited by 11
“Indeed, both amylin and GIP analogs failed to show convincing effects in rodents [ 166–169], yet mimicking these hormones turned out to be transformative in humans when combined with GLP-1 [15, 148, 151, 152, 170, 171].”
Tirzepatide reduces alcohol drinking and relapse-like behaviours in rodents
Edvardsson, C. E., Adermark, L., Gottlieb, S., Alfreji, S., Emous, T. A., Gouda, Y., Thorsell, A., Vujičić, M., Aranäs, C., Benrick, A., et al. (2026) · EBioMedicine · doi:10.1016/j.ebiom.2025.106119 · Cited by 16
“20,33,34 Tirzepa-tide exhibits higher binding affinity for GIPR than GLP-1R while maintaining distinct GLP-1R signalling properties, 35 which may be particularly relevant given recent evidence suggesting that GIPR influences addiction processes independently and in combination with GLP-1R.”
Gu, S. (2026) · Drug Healthcare and Patient Safety · doi:10.2147/dhps.s556918 · Cited by 15
“6,7 It outperformed semaglutide in HbA1c reduction, achieved average weight loss up to 20.9% at 72 weeks, 8,9 and reduced the risk of cardiovascular death or worsening heart failure by 38%.”
InfluentialDo no harm: managing nausea and vomiting in GLP-1 based obesity therapies
Alhazmi, A., & le Roux, C. W. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1788698 · Cited by 10
Gasoyan, H., Schulte, R. J., Boyer, C., Casacchia, N. J., Butsch, W. S., Le, P. N. B., Aminian, A., Griebeler, M. L., Burguera, B. G., & Rothberg, M. B. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70660 · Cited by 13
Xie, Y., Choi, T., & Al-Aly, Z. (2026) · BMJ Medicine · doi:10.1136/bmjmed-2025-002150 · Cited by 8
Setmelanotide for the Treatment of Acquired Hypothalamic Obesity
Miller, J. L., van Santen, H. M., Phillips, S. A., Hamilton, J., Aberle, J., Sathyapalan, T., Mohamed, Z., McCormack, S. E., Shoemaker, A. H., Kelsey, M. M., et al. (2026) · New England Journal of Medicine · doi:10.1056/nejmoa2512275 · Cited by 17
HIV and obesity: updates in management strategies
Parra-Rodriguez, L., & O’Halloran, J. A. (2023) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0000000000000781 · Cited by 10
Obesity and Kidney Transplantation—How to Evaluate, What to Do, and Outcomes
Cocco, P. D., Bencini, G., Spaggiari, M., Petrochenkov, E., Akshelyan, S., Fratti, A., Zhang, J. C., Alvarez, J. A. A., Tzvetanov, I. G., & Benedetti, E. (2023) · Transplantation · doi:10.1097/tp.0000000000004564 · Cited by 9
Pharmacotherapy for chronic obesity management: a look into the future
Abdel-Malek, M., Yang, L., & Miras, A. D. (2023) · Internal and Emergency Medicine · doi:10.1007/s11739-023-03237-4 · Cited by 14
The ‘Behavioral Balance Model’: A new perspective on the aetiology and therapy of obesity
Schultes, B., Ernst, B., Hallschmid, M., Bueter, M., & Meyhöfer, S. M. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15271 · Cited by 10
“…tirzepatide that agonistically acts on both the GLP-1 receptor as well as on the glucose-dependent insulinotropic polypeptide receptor has recently been shown to reduce body weight by 20.9% over a 72-week treatment period, 82 i.e. to induce a pharmacological weight reduction never seen before.”
BackgroundInfluentialMody, R., Meyer, K. L., Ward, J. M., & O’Day, K. (2023) · Diabetes Therapy · doi:10.1007/s13300-023-01470-w · Cited by 10
Emerging Medical Therapies for the Treatment of Obesity in Women with Cardiovascular Diseases
Behrooz, L., Lenneman, C. G., & Hamburg, N. M. (2023) · Current Cardiology Reports · doi:10.1007/s11886-023-01961-z · Cited by 9
Can liquid biopsies for MASH help increase the penetration of metabolic surgery? A narrative review
Castagneto‐Gissey, L., Bornstein, S. R., & Mingrone, G. (2023) · Metabolism · doi:10.1016/j.metabol.2023.155721 · Cited by 8
Shah, N. P., Lü, R., Haddad, F., Shore, S., Schaack, T., Mega, J. L., Pagidipati, N. J., Palaniappan, L. P., Mahaffey, K. W., Shah, S. H., et al. (2024) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2024.100646 · Cited by 10
Next Generation Weight Loss Drugs for the Prevention of Cancer?
Carbonell, C., Stephen, M. M., Ruan, Y., Warkentin, M. T., & Brenner, D. R. (2024) · Cancer Control · doi:10.1177/10732748241241158 · Cited by 14
“14-17 , 20 Perhaps most staggering from these trials are the”
BackgroundPractical strategies to manage obesity in type 2 diabetes
Rodbard, H. W., Barnard-Kelly, K. D., Pfeiffer, A. F. H., Mauersberger, C., Schnell, O., & Giorgino, F. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15556 · Cited by 10
Current State of Pharmacotherapy in Obesity
Kim, W. J. (2024) · Korean Journal of Gastroenterology · doi:10.4166/kjg.2024.016 · Cited by 10
Continuous positive airway pressure is here to stay
Malhotra, A., & Pettus, J. (2024) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(23)00469-1 · Cited by 8
GLP-1 Receptor Agonists and Cardiovascular Disease: What Do Clinicians Need to Know?
Hayat, J., Shah, N. P., Agarwala, A., Khan, M. S., & Butler, J. (2024) · Current Atherosclerosis Reports · doi:10.1007/s11883-024-01214-6 · Cited by 11
“Apart from glycemic control, tirzepatide has recently been approved by FDA for weight management in patients with overweight or obesity based on the findings of SUR-MOUNT-1 and –2 [46, 47] of the SURMOUNT clinical trial program.”
Pharmacotherapy for older people with obesity
Boyle, L. D., Akbaş, F., Yazıcı, D., McGowan, B. M., & Yumuk, V. (2024) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2024.05.006 · Cited by 10
Metadata
- Authors
- Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., & Stefanski, A.
- Affiliations
- Eli Lilly (United States) (US)
- From the Section of Endocrinology and Metabolism, Department of Medicine, and the Section of Pediatric Endocrinology, Department of Pediatrics, Yale University School of Medicine, New Haven, CT (A.M.J.); the Comprehensive Weight Control Center, Division of Endocrinology, Diabetes, and Metabolism, Weill Cornell Medicine, New York (L.J.A.); Eli Lilly, Indianapolis (N.N.A., S.Z., B.L., M.C.B., A.S.); McMaster University, Hamilton, and York University and Wharton Weight Management Clinic, Toronto — all in Ontario, Canada (S.W.); Intend Research, Norman, OK (L.C.); Centro Paulista De Investigação Clínica (Cepic), Sao Paulo (B.A.); and Tokyo-Eki Center-Building Clinic, Tokyo (A.K.).
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2022-07-21
- Volume
- 387
- Issue
- 3
- Pages
- 205-216
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4281934192
- Semantic Scholar
- 3fb03384cc726ebd9d08c76482e6edf35502d0c7
- Cited by
- 3,838
- References
- 28
- Citations by year
- 2026: 1279 · 2025: 1067 · 2024: 776 · 2023: 562 · 2022: 149
- FWCI
- 382.29
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Eli Lilly and Company
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Keywords
- tirzepatide, obesity, weight loss, GLP-1 receptor agonists, GIP receptor agonist, glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, dose escalation, body mass index, weight-related comorbidities, treatment discontinuation, treatment-emergent adverse events, drug safety, subcutaneous administration
- MeSH terms
- Tirzepatide, Adult, Dose-Response Relationship, Drug, Double-Blind Method, Glucagon-Like Peptides, Gastric Inhibitory Polypeptide, Humans, Injections, Subcutaneous, Obesity, Weight Loss, Treatment Outcome, Anti-Obesity Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.